000 01724 a2200565 4500
005 20250516150724.0
264 0 _c20140310
008 201403s 0 0 eng d
022 _a1476-5551
024 7 _a10.1038/leu.2013.147
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBernot, K M
245 0 0 _aToward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.
_h[electronic resource]
260 _bLeukemia
_cDec 2013
300 _a2379-82 p.
_bdigital
500 _aPublication Type: Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650 0 4 _aAnimals
650 0 4 _aEpigenesis, Genetic
650 0 4 _aHistone-Lysine N-Methyltransferase
650 0 4 _aHumans
650 0 4 _aLeukemia, Myeloid, Acute
_xgenetics
650 0 4 _aMice
650 0 4 _aMice, Knockout
650 0 4 _aMyeloid-Lymphoid Leukemia Protein
_xgenetics
650 0 4 _aPrecision Medicine
700 1 _aSiebenaler, R F
700 1 _aWhitman, S P
700 1 _aZorko, N A
700 1 _aMarcucci, G G
700 1 _aSanthanam, R
700 1 _aAhmed, E H
700 1 _aNgangana, M
700 1 _aMcConnell, K K
700 1 _aNemer, J S
700 1 _aBrook, D L
700 1 _aKulp, S K
700 1 _aChen, C S
700 1 _aFrankhouser, D
700 1 _aYan, P
700 1 _aBundschuh, R
700 1 _aZhang, X
700 1 _aDorrance, A M
700 1 _aDickerson, K E
700 1 _aJarjoura, D
700 1 _aBlum, W
700 1 _aMarcucci, G
700 1 _aCaligiuri, M A
773 0 _tLeukemia
_gvol. 27
_gno. 12
_gp. 2379-82
856 4 0 _uhttps://doi.org/10.1038/leu.2013.147
_zAvailable from publisher's website
999 _c22738430
_d22738430